Navigation Links
Quantel Medical Receives FDA Clearance for new Vitra Multispot Laser System
Date:3/20/2013

CLERMONT-FERRAND, France, March 20, 2013 /PRNewswire/ -- Quantel Medical today announced the U.S. Food and Drug Administration (FDA) 510(k) market clearance of the Vitra Multispot™ laser.  The product was developed by Quantel Medical to give access to advanced pattern-scanning technology to ophthalmology practices worldwide though intelligent design.

"Ophthalmologists now can choose a laser that is designed specifically to help them respond to the burgeoning diabetes epidemic," stated Mr. Jean-Marc Gendre , CEO of Quantel Medical. "Efficient and less-painful pattern-scanning delivery of laser to treat diabetic eye disease is no longer reserved for the elite treatment centers."

The Vitra Multispot combines advanced pattern scanning and solid-state green laser technologies in a compact portable platform. This intelligent design delivers a cost-effective solution to ophthalmologists around the world dealing with epidemic levels of diabetic eye disease in their patient populations, including ophthalmologists in U.S. managing current and future eye disease among the estimated 8.5 million Americans diagnosed with diabetes and an estimated 79 million Americans categorized as pre-diabetic by the American Diabetes Association.

Rama D. Jager, MD, MBA, FACS of University Retina, Oak Forest, Illinois, was the first user of the Vitra Multispot in the U.S.  Dr. Jager commented, "The Vitra Multispot has accelerated our capability to manage the growing number of diabetic patients coming to our practice for care and improved our reputation for superior patient care since the pattern-scanning laser treatment with the Vitra Multispot is less painful compared to the previous treatments many patients received with a conventional laser."

The introduction of the Vitra Multispot follows a long history of first-to-market introductions for Quantel Medical. Quantel was the first company to develop and introduce a solid-state green photocoagulator in 1993, followed by the first solid-state yellow photocoagulator in 1998 for ophthalmic treatments. The Vitra Multispot completes Quantel's comprehensive line of photocoagulators, ranging from the Vitra™ 532nm mono-spot system to the SupraScan™ 577nm multi-spot platform.

About Quantel Medical

Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions, and a comprehensive product portfolio of diagnostic ultrasound and surgical lasers for ophthalmologists. The products are available through direct sales operations in the U.S. and France, and through independent distributors in over 80 countries.

Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid-state lasers for scientific and industrial applications.

www.quantel-medical.com


'/>"/>
SOURCE Quantel Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Medical Device Developers - Network at BIOMEDevice Boston Next Week
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
7. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Essential Medical Dismisses Patent Case against Masimo and Cercacor
10. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
11. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):